Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Comparative efficacy and safety of obinutuzumab- versus rituximab-based immunochemotherapy in newly diagnosed burkitt lymphoma: A single-center retrospective study

Ying Zhang, Wei Guo, Haotian Wang et al. Nov 03, 2025 pp. 6886-6886 10.1182/blood-2025-6886

Abstract Background: Burkitt lymphoma (BL) is a highly aggressive B-cell malignancy requiring intensive immunochemotherapy. While rituximab(...

Efficacy and safety of zanubrutinib combined with chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma

Hongyun Xing Nov 03, 2025 pp. 7218-7218 10.1182/blood-2025-7218

Abstract Background Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. Approximately 30%-40% of patients...

Acquired Hemophilia A (AHA) associated with monoclonal gammopathy: A single institution case series

Saumya Easaw, Reed Friend Nov 03, 2025 pp. 3088-3088 10.1182/blood-2025-3088

Abstract Case 1: A 68-year-old woman with IgA lambda monoclonal gammopathy of undetermined significance (MGUS) and beta...

The efficacy of short-course blinatumomab immunotherapy as a bridge-to-HSCT in ph-negative B-cell acute lymphoblastic leukemia

xia Shao, Jiahua Niu, Ruiqi Li et al. Nov 03, 2025 pp. 6078-6078 10.1182/blood-2025-6078

Abstract Introduction Although allogeneic hematopoietic stem cell transplantation (allo-HSCT) provides a potential cure for patients with Ph...

Germline genetic testing uncovers a high frequency of inborn error of immunity diagnoses in children with single and multi-lineage immune cytopenias in a large US cohort

Emily Harris, Thomas Pincez, Kirsty Hillier et al. Nov 03, 2025 pp. 630-630 10.1182/blood-2025-630

Abstract Background Immune cytopenias including Immune Thrombocytopenia (ITP), Autoimmune Hemolytic Anemia (AIHA), or multilineage immune cy...

Chorionic villus sampling acceptability and therapeutic abortion compliance in beta-thalassemia minor parents: A study in low-middle income country

Laila Bahadur, Zohra Wazir, Khalil Rahman et al. Nov 03, 2025 pp. 4449-4449 10.1182/blood-2025-4449

Abstract Introduction: Beta-thalassemia is the most prevalent hemoglobin disorder in Pakistan, posing a significant disease burden. Prenatal...

Overlap of post-CAR T HLH toxicity definitions and their prognostic significance in children and young adults with B-acute lymphoblastic leukemia

Kevin McNerney, Soyang Kwon, Swati Naik et al. Nov 03, 2025 pp. 4501-4501 10.1182/blood-2025-4501

Abstract Introduction: Hemophagocytic lymphohistiocytosis (HLH) toxicities are increasingly recognized following chimeric antigen receptor (...

Functional annotation of MPN clones reveals mutation-specific fitness and fate bias

Franco Castillo Tokumori, Daniel Choi, Ghaith Abu-Zeinah et al. Nov 03, 2025 pp. 3766-3766 10.1182/blood-2025-3766

Abstract Introduction Improving outcomes for patients with myeloproliferative neoplasms (MPNs) requires therapies that prolong event-free sur...

Quality and timing of patient-reported outcome reports in randomized controlled trials (RCTs) of patients with lymphoid malignancies: Analysis of 83 RCTs published between 2015 and 2025

Fabio Efficace, David Cella, Neil Aaronson et al. Nov 03, 2025 pp. 4408-4408 10.1182/blood-2025-4408

Abstract Background Patient-Reported Outcomes (PROs), including quality of life or symptoms, are now frequently used as endpoints in RCTs te...

Mitochondria contribute to naip/NLRC4 inflammasome assembly and activation in macrophage

Ling Yang, Yan Zhang, Zhuodong Chai et al. Nov 03, 2025 pp. 2983-2983 10.1182/blood-2025-2983

Abstract Macrophages play a crucial role in both innate immunity and inflammation. The NAIP/NLRC4 inflammasome is an imm...

High dose ascorbate downregulates innate immune cytokines in the bone marrow of TET2 mutant chronic myelomonocytic leukemia

Maha Kamel, Monika Kutyna, Nirmal Robinson et al. Nov 03, 2025 pp. 2065-2065 10.1182/blood-2025-2065

Abstract The most frequent mutation in CMML is a loss of function missense or frameshift variant in the gene encoding the epigenetic dioxyge...

CPX-351 is effective in secondary Acute Myeloid Leukemia, regardless if defined according to 2016 or 2022 edition of who classification.

Fabio Guolo, Carola Riva, Enrico Carminati et al. Nov 03, 2025 pp. 1629-1629 10.1182/blood-2025-1629

Abstract Background and aims: The definition of secondary Acute Myeloid Leukemia (s-AML) has significantly changed from the previous WHO cla...

Effects of vaso-occlusive episodes, acute kidney injury, and APOL1 status on urine albumin concentration in patients with sickle cell disease

Chang Xu, Maria Armila Ruiz, Jin Han et al. Nov 03, 2025 pp. 1164-1164 10.1182/blood-2025-1164

Abstract Introduction: Chronic kidney disease (CKD) is a common complication associated with substantial morbidity and early mortality in pe...

Safety and efficacy of the JAK/rock inhibitor rovadicitinib in combination with the bromodomain and extra-terminal inhibitor TQB3617 in patients with myelofibrosis: A phase ib/II study

Chunkang Chang, Xuliang Shen, Hu Zhou et al. Nov 03, 2025 pp. 481-481 10.1182/blood-2025-481

Abstract Introduction: Rovadicitinib (R, TQ05105) is a novel, oral small-molecule JAK/ROCK inhibitor that has demonstrat...

Risk factors for thrombo-embolism in neonates: A systematic review of the literature and call to action

Marie-Claude Pelland-Marcotte, Elisabeth Boileau, Norma Maria Perez Herrera et al. Nov 03, 2025 pp. 4900-4900 10.1182/blood-2025-4900

Abstract BACKGROUND: While venous thrombo-embolism (VTE) is increasingly recognized in neonates and prothrombotic risk factors are increasin...

Fucosylation of human hematopoietic stem cells enhances engraftment and self-renewal through modulated e-selectin interactions and intracellular signaling

Asma Al-Amoodi, Arwa Alghuneim, Jana Malki et al. Nov 03, 2025 pp. 7616-7616 10.1182/blood-2025-7616

Abstract Hematopoietic stem cell transplantation (HSCT) efficacy is often limited by inefficient stem cell delivery to the bone marrow and c...

Sequencing CD20-directed bispecific antibody and CD19-directed CAR T cell therapy in large B cell lymphoma: A multicenter real-world study

David Qualls, Andrew Jallouk, Geoffrey Shouse et al. Nov 03, 2025 pp. 3663-3663 10.1182/blood-2025-3663

Abstract Introduction Multiple T-cell engaging therapies, including CD20-directed bispecific antibodies (BsAb) and CD19-directed chimeric ant...

Comparative analysis of mortality trends in acute versus chronic lymphoid leukemia in the u.S. population: A CDC wonder-based study (1999–2023).

Sheraz Qasim, Muhammad Saim, Ali Hassan et al. Nov 03, 2025 pp. 8182-8182 10.1182/blood-2025-8182

Abstract Introduction: Lymphoid leukemia, having acute(ALL) and chronic(CLL) forms, is a malignancy of the blood and bone marrow that disrup...

Targeting CPNE8 suppresses HOXA9-dependent AML progression and overcomes chemotherapy resistance

Wenjing Shu, Yuncan Cao, Xiaojin Lin et al. Nov 03, 2025 pp. 870-870 10.1182/blood-2025-870

Abstract Background Acute myeloid leukemia (AML) remains a challenge in treatment and mechanisms understanding in disease progression and th...

Racial disparities on incidence and survival in Mantle Cell Lymphoma: A surveillance, epidemiology and end results program database (2013-2022) retrospective analysis

Emanuel Vanegas, Aye Thida, Vladimir Gotlieb Nov 03, 2025 pp. 8035-8035 10.1182/blood-2025-8035

Abstract Background: Mantle cell lymphoma (MCL) is a rare and aggressive subtype of B-cell non-Hodgkin lymphoma, accounting for approximatel...

Synthetic lethal targeting of PSMC2-dependent p97-adapted proteasome complexes that confer chemoresistance in multiple myeloma

James Driscoll, James Ignatz-Hoover, Ehsan Malek et al. Nov 03, 2025 pp. 2176-2176 10.1182/blood-2025-2176

Abstract Introduction. Multiple myeloma (MM) is the second most common hematological malignancy. The emergence of novel agents has significa...

A decade of progress: A comparative analysis of real-world survival in chronic lymphocytic leukemia across therapeutic eras

Mostafa Eysha, David Elliott, Alaaeddine El Ghazawi et al. Nov 03, 2025 pp. 3911-3911 10.1182/blood-2025-3911

Abstract Introduction Management of chronic lymphocytic leukemia (CLL) has advanced significantly over the past two decades with the introduc...

Apcin-derived CDC20 inhibitors synergize with microtubule disruptors to induce mitotic catastrophe in acute leukemias

Andrea Marranci, Gabriele Micheletti, Francesco Olimpico et al. Nov 03, 2025 pp. 1717-1717 10.1182/blood-2025-1717

Abstract CDC20, a coactivator of the Anaphase-Promoting Complex/Cyclosome (APC/C), is a key regulator of chromosome segregation and mitotic...

Advancing strategies to improve chemotherapy adherence in young children with ALL: Understanding the role of behavioral parenting skills and daily barriers to identify novel intervention targets

Elizabeth Bouchard, Sharon Castellino, Gregory Fabiano et al. Nov 03, 2025 pp. 6274-6274 10.1182/blood-2025-6274

Abstract Introduction: Adherence to oral anti-cancer therapies is a critical concern in pediatric oncology, and studies consistently documen...

Elevated circulating activated FOXP3+ regulatory T cell subset in patients with advanced chronic lymphocytic leukemia as a marker for severe infections during 1000 days of follow-up

Mojca Dreisinger, Zlatko Roškar, Matjaz Sever et al. Nov 03, 2025 pp. 3904-3904 10.1182/blood-2025-3904

Abstract Introduction. Patients with chronic lymphocytic leukemia (CLL) are more susceptible to infections, which remain the leading cause of...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page